Clinical Trial Update: Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating CCI-779 (temsirolimus) in combination with letrozole for post-menopausal women with breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CCI-779 (temsirolimus)
• Letrozole (letrozole)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Status: TERMINATED